Winstrol is one of the most famous steroids of all time, mainly thanks to a man named Ben Johnson.
In 1988, Johnson was the reigning world champion in the 100-meter dash, widely considered the most prestigious of all track and field events.
He had set a world record a year before, beating Carl Lewis with a time of 9.83 seconds. He was instantly propelled to world fame, reportedly making almost $500,000 a month from endorsements.
He was showered in accolades including the Lou Marsh Trophy and Lionel Conacher Award, and was named the Associated Press Athlete of the Year for 1987.
Johnson cemented his status as the golden boy of track and field on September 24, 1988, in one of the most competitive 100-meter races ever run, when he sprinted to an Olympic gold medal and a new world record of 9.79 seconds.
Unfortunately, this would be the capstone of his career.
Three days later, the Olympic Doping Control Center found traces of an anabolic steroid in Johnson’s urine sample.
Stanozolol, aka Winstrol.
Johnson denied taking steroids at first, but was promptly stripped of his new world record and the one he’d set a year before. Later, he admitted to taking steroids such as Winstrol and testosterone since 1981, and was banned for life from professional sprinting after he failed another drug test in 1993.
Although Johnson made stanozolol famous, it’s been used by sprinters, bodybuilders, and athletes of all stripes long before Johnson got busted and is still used today.
It’s known as one of the best steroids for cutting, helping people gain moderate amounts of muscle without any increase in water weight or body fat.
What does the science say, though?
Why are athletes still risking their careers to reap its benefits?
And, what are the side effects?
In this podcast, you’re going to learn the answers to all of these questions and more. You’ll learn . . .
- What Winstrol is
- Why people take Winstrol
- What the Winstrol side effects are
- How to tell if someone is taking Winstrol
- And more.
Let’s get started.
Lastly, if you want to support the show, please drop a quick review of it over on iTunes. It really helps!
Mentioned on the show:
What did you think of this episode? Have anything else to share? Let me know in the comments below!
+ Scientific References
- Falliers, C. J., Jorgensen, J. R., Tan, L. S., & Bukantz, S. C. (1963). Anabolic Effects of Stanozolol: Reversal of Growth Arrest and Possible Changes in Adult Height Prognosis Among Children With Intractable Asthma Treated With Corticosteroids. American Journal of Diseases of Children, 106(4), 388–401. https://doi.org/10.1001/archpedi.1963.02080050390008
- Kiraly, C. L., Collan, Y., & Alen, M. (1987). Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. American Journal of Dermatopathology, 9(6), 515–519. https://doi.org/10.1097/00000372-198712000-00008
- Skroza, N., Tolino, E., Mambrin, A., Zuber, S., Balduzzi, V., Marchesiello, A., Bernardini, N. T., Proietti, I., & Potenza, C. (2018). Adult acne versus adolescent acne: A retrospective study of 1,167 Patients. Journal of Clinical and Aesthetic Dermatology, 11(1), 21–25. /pmc/articles/PMC5788264/?report=abstract
- Lynn, D., Umari, T., Dellavalle, R., & Dunnick, C. (2016). The epidemiology of acne vulgaris in late adolescence. Adolescent Health, Medicine and Therapeutics, 7, 13. https://doi.org/10.2147/ahmt.s55832
- Hoffman, J. R., & Ratamess, N. A. (2006). Medical issues associated with anabolic steroid use: are they exaggerated? Journal of Sports Science & Medicine, 5(2), 182–193. http://www.ncbi.nlm.nih.gov/pubmed/24259990
- Kerr, J. B., & Sharpe, R. M. (1985). Follicle-stimulating hormone induction of ley dig cell maturation. Endocrinology, 116(6), 2592–2604. https://doi.org/10.1210/endo-116-6-2592
- Nedresky, D., & Singh, G. (2019). Physiology, Luteinizing Hormone. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/pubmed/30969514
- Rosenfield, R. L., Perovic, N., Ehrmann, D. A., & Barnes, R. B. (1996). Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. The Journal of Clinical Endocrinology & Metabolism, 81(9), 3408–3411. https://doi.org/10.1210/jcem.81.9.8784105
- Burger, H. G. (2002). Androgen production in women. Fertility and Sterility, 77(SUPPL. 4), 3–5. https://doi.org/10.1016/s0015-0282(02)02985-0
- Tyagi, V., Scordo, M., Yoon, R. S., Liporace, F. A., & Greene, L. W. (2017). Revisiting the role of testosterone: Are we missing something? Reviews in Urology, 19(1), 16–24. https://doi.org/10.3909/riu0716
- Hardt, A., Stippel, D., Odenthal, M., Hölscher, A. H., Dienes, H.-P., & Drebber, U. (2012). Development of Hepatocellular Carcinoma Associated with Anabolic Androgenic Steroid Abuse in a Young Bodybuilder: A Case Report. Case Reports in Pathology, 2012, 1–5. https://doi.org/10.1155/2012/195607
- Gorayski, P., Thompson, C. H., Subhash, H. S., & Thomas, A. C. (2008). Hepatocellular carcinoma associated with recreational anabolic steroid use. British Journal of Sports Medicine, 42(1), 74–75. https://doi.org/10.1136/bjsm.2007.03932
- Evert, M., & Dombrowski, F. (2008). Hepatozelluläre karzinome in der nichtzirrhotischen leber. Pathologe, 29(1), 47–52. https://doi.org/10.1007/s00292-007-0953-3
- Hernandez‐Nieto, L., Bruguera, M., Bombi, J. A., Camacho, L., & Rozman, C. (1977). Benign liver‐cell adenoma associated with long‐term administration of an androgenic‐anabolic steroid (methandienone). Cancer, 40(4), 1761–1764. https://doi.org/10.1002/1097-0142(197710)40:4<1761::AID-CNCR2820400454>3.0.CO;2-C
- Winwood, P. J., Robertson, D. A. F., & Wright, R. (1990). Bleeding oesophageal varices associated with anabolic steroid use in an athlete. Postgraduate Medical Journal, 66(780), 864–865. https://doi.org/10.1136/pgmj.66.780.864
- Ahlgrim, C., & Guglin, M. (2009). Anabolics and Cardiomyopathy in a Bodybuilder: Case Report and Literature Review. Journal of Cardiac Failure, 15(6), 496–500. https://doi.org/10.1016/j.cardfail.2008.12.014
- Štimac, D., Milić, S., Dintinjana, R. D., Kovač, D., & Ristić, S. (2002). Androgenic/anabolic steroid-induced toxic hepatitis. Journal of Clinical Gastroenterology, 35(4), 350–352. https://doi.org/10.1097/00004836-200210000-00013
- Nguyen, K. D., Sundaram, V., & Ayoub, W. S. (2014). Atypical causes of cholestasis. World Journal of Gastroenterology, 20(28), 9418–9426. https://doi.org/10.3748/wjg.v20.i28.9418
- Sánchez-Osorio, M., Duarte-Rojo, A., Martínez-Benítez, B., Torre, A., & Uribe, M. (2008). Anabolic-androgenic steroids and liver injury. Liver International, 28(2), 278–282. https://doi.org/10.1111/j.1478-3231.2007.01579.x
- Krüskemper, H. L., & Noell, G. (1966). Liver toxicity of a new anabolic agent: Methyltrienolone (17α-Methyl-4,9,11-estratriene-17β-ol-3-one). Steroids, 8(1), 13–24. https://doi.org/10.1016/0039-128X(66)90114-0
- Hinchliffe, S. A., Woods, S., Gray, S., & Burt, A. D. (1996). Cellular distribution of androgen receptors in the liver. Journal of Clinical Pathology, 49(5), 418–420. https://doi.org/10.1136/jcp.49.5.418
- Labrie, F., Luu-The, V., Lin, S. X., Labrie, C., Simard, J., Breton, R., & Bélanger, A. (1997). The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids, 62(1), 148–158. https://doi.org/10.1016/S0039-128X(96)00174-2
- Plymate, S. R., Leonard, J. M., Paulsen, C. A., Fariss, B. L., & Karpas, A. E. (1983). Sex hormone-binding globulin changes with androgen replacement. Journal of Clinical Endocrinology and Metabolism, 57(3), 645–648. https://doi.org/10.1210/jcem-57-3-645
- Sinnecker, G., & Köhler, S. (1989). Sex hormone-binding globulin response to the anabolic steroid stanozolol: Evidence for its suitability as a biological androgen sensitivity test. Journal of Clinical Endocrinology and Metabolism, 68(6), 1195–1200. https://doi.org/10.1210/jcem-68-6-1195
- Selby, C. (1990). Sex hormone binding globulin: Origin, function and clinical significance. In Annals of Clinical Biochemistry (Vol. 27, Issue 6, pp. 532–541). Ann Clin Biochem. https://doi.org/10.1177/000456329002700603
- Jarvis, C. I., Lynch, A. M., & Morin, A. K. (2008). Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. In Annals of Pharmacotherapy (Vol. 42, Issues 7–8, pp. 967–978). https://doi.org/10.1345/aph.1K673
- Rance, N. E., & Max, S. R. (1984). Modulation of the cytosolic androgen receptor in striated muscle by sex steroids. Endocrinology, 115(3), 862–866. https://doi.org/10.1210/endo-115-3-862
- Hobbs, C. J., Plymate, S. R., Rosen, C. J., & Adler, R. A. (1993). Testosterone administration increases insulin-like growth factor-I levels in normal men. Journal of Clinical Endocrinology and Metabolism, 77(3), 776–779. https://doi.org/10.1210/jcem.77.3.7690364
- Knudsen, J. F., & Max, S. R. (1980). Aromatization of androgens to estrogens mediates increased activity of glucose 6-phosphate dehydrogenase in rat levator ani muscle. Endocrinology, 106(2), 440–443. https://doi.org/10.1210/endo-106-2-440
- Schulster, M., Bernie, A. M., & Ramasamy, R. (2016). The role of estradiol in male reproductive function. In Asian Journal of Andrology (Vol. 18, Issue 3, pp. 435–440). Medknow Publications. https://doi.org/10.4103/1008-682X.173932
- Kicman, A. T. (2008). Pharmacology of anabolic steroids. In British Journal of Pharmacology (Vol. 154, Issue 3, pp. 502–521). Wiley-Blackwell. https://doi.org/10.1038/bjp.2008.165
- Davey, R. A., & Grossmann, M. (2016). Androgen Receptor Structure, Function and Biology: From Bench to Bedside. The Clinical Biochemist. Reviews, 37(1), 3–15. http://www.ncbi.nlm.nih.gov/pubmed/27057074
- Ustuner, E. T. (2013). Cause of androgenic alopecia: Crux of the matter. Plastic and Reconstructive Surgery, 1(7). https://doi.org/10.1097/GOX.0000000000000005